Research
Hormonal
GLP-1/dual agonists were associated with a 54% lower incidence of physician-reported sleep apnea (PRSA).
Practitioners may consider GLP-1/dual agonists as a treatment option to reduce the incidence of sleep apnea in patients with obesity and type 2 diabetes.
StrongSupportsmedium confidence
Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR, 0.46 [95% CI, 0.45-0.49]).
Why this rating
Based on a large retrospective cohort study design.
Source
Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study
Beatriz S Prado et al. · Annals of the American Thoracic Society · 2026
cohort · n=1253188Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →